Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Kriya Therapeutics develops gene therapies for conditions affecting millions of people globally, with a focus on making these therapies accessible. The company targets areas of high unmet need, utilizing innovative gene therapy approaches.

Kriya Therapeutics

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies, Inc.

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

Rock Springs Capital

Sabby Capital

Redmile Group

Venrock

Adage Capital Management

Deerfield

Adverum Biotechnologies

Today, we announced the appointment of Dr. C. David Nicholson to Adverum's Board of Directors, bringing extensive expertise as we advance our gene therapy mission. Learn more here: https://bit.ly/3Qtn6y9
#Gtx #AAV7m8

Today, we announced 3-year efficacy and safety results from the OPTIC extension study in patients with wet AMD during the Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California. Learn more here: https://bit.ly/3FJGkL1
#AAO2023 #Gtx #AAV7m8

Today, we announced positive aflibercept protein level data from our ongoing LUNA Phase 2 trial evaluating Ixo-vec for the treatment of wet AMD. Read here for more details: https://bit.ly/3ZvCmi6

Adverum is pleased to welcome Andy Ramelmeier, Ph.D., as our Chief Technology Officer. Dr. Ramelmeier brings more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapies. #gtx7m8

Today, we announced full enrollment in LUNA, our Phase 2 clinical trial evaluating Ixo-vec for the treatment of wet age-related macular degeneration, and reported financial results for the second quarter. Read here for more details: https://bit.ly/45qDcib

Celebrating Juneteenth: Honoring freedom, equality, and the resilience of Black communities. As a company holiday, we encourage our employees to use today to amplify voices, educate, and make a difference. Together, let's commemorate this historic day and work towards a more inclusive future. #Juneteenth

Today, we announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York. The on-demand webcast fireside may be accessed for 90 days here: https://bit.ly/3C5hzaz #JefferiesHealthcare

We are excited to share more about our data being presented at the American Society of Gene & Cell Therapy 2023 Annual Meeting, including data that supports the two doses being evaluated in our LUNA trial and a new program for Geographic Atrophy. Read more about our poster and oral presentations on the Publications page of the Adverum website: https://lnkd.in/gHFrbeHj #aav7m8 #gtx7m8

Metric
Company Name	Hera BioLabs	Kriya Therapeutics
Symbol
MSH ID	COM:HERABIOLABS	COM:KRIYATHERAPEUTICS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Venture Round
Employee Count
Website	herabiolabs.com	kriyatherapeutics.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.41K
Web Traffic Growth	-0.46
Valuation
Raised Capital	1.07M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ADVERUM

Adverum Biotechnologies

Last Close

5.75

22/11 21:00

Market Cap

161.49M

Beta: -

Volume Today

440.65K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue